PO.BCS01.05 · 生物信息与计算

单细胞分辨率下人远端胆管癌导管细胞的共有与分化转录特征

Shared and divergent transcriptional signatures of ductal cells in distal human cholangiocarcinoma at a single cell resolution

海报缩略图:单细胞分辨率下人远端胆管癌导管细胞的共有与分化转录特征
编号 5439 展板 6 时间 4/21 02:00–05:00 区域 Section 1 主讲 Meng Ting Chen, BA
分会场 Application of Bioinformatics to Cancer Biology 5
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Meng Ting Chen1, Jon M. Harrison1, David R. Ruddy2, Michelle Piquette2, Jon Chang2, Viviana Cremasco2, Andrew L. Warshaw1, Carlos Fernandez-Del Castillo1, Andrew S. Liss1, Divyansh Agarwal1

1Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA,2Novartis Institutes for BioMedical Research, Cambridge, MA

摘要 Abstract

中文摘要
背景:虽然慢性胰腺炎(CP)长期以来被认为是胰腺导管腺癌的危险因素,但近期研究表明胰腺炎患者发生胆道恶性肿瘤的风险升高。然而,其潜在机制以及可能解释这种关联的基因组相似性仍不明确。炎症被认为是胆管癌的一个诱发危险因素;然而,慢性胰腺炎的炎症环境是否也促成这种风险尚不清楚。为填补这一空白,我们表征了慢性胰腺炎患者与远端胆管癌(dCCA)患者之间,相较于正常健康个体的共有和独特基因组特征。 方法:我们对取自3例健康人受试者、3例CP患者和2例dCCA个体的胰腺或肿瘤标本进行了单细胞RNA测序(scRNA-seq)。在赋予细胞类型身份并划分导管细胞簇后,我们对来自三个患者队列(正常、CP和dCCA)导管细胞的拷贝数变异以及基因和通路水平的功能扰动进行了推断。 结果:scRNA-seq在三个患者队列约120,000个细胞中揭示了35个不同的细胞簇。基于半监督学习,我们在数据中鉴定出13种细胞类型;进一步分析显示,导管细胞簇可进一步细分为两个具有不同基因组特征的细胞群。我们通过两种正交方法进一步在dCCA队列的Ductal A簇中鉴定出1、7、11、12和18号染色体的扩增/重复。假散装(Pseudobulking)分析提示Ductal A亚簇中层粘连蛋白的上调,配体-受体分析进一步揭示LAMC2是导管细胞簇中的一个关键靶基因,推测存在由TGFB1和FGF2受体介导的纤维炎症。虽然层粘连蛋白上调是dCCA所特有的,在CP中未观察到,但TGFB1和FGF2受体驱动的信号传导是CP和dCCA导管细胞中共有的特征。 结论:我们在dCCA中发现了一个新的导管细胞群,与正常胰腺和CP相比,该细胞群表现出层粘连蛋白的上调。此外,dCCA细胞外基质中配体、受体和靶基因的表达突显了TGFB1-FGF2-LAMC2轴可能如何促成dCCA肿瘤中所观察到的促纤维增生过程。
查看英文原文 English abstract
Background: While chronic pancreatitis (CP) has long been recognized as a risk factor for pancreatic ductal adenocarcinoma, recent work has shown an elevated risk of biliary tract malignancies in patients with pancreatitis. However, the underlying mechanisms and the genomic similarities that might explicate this association remain elusive. Inflammation is thought to be a precipitating risk factor for cholangiocarcinoma; however, whether the inflammatory milieu of chronic pancreatitis also contributes to this risk is unclear. To address this gap, we characterized the shared and unique genomic signatures between patients with chronic pancreatitis and those with distal cholangiocarcinoma (dCCA), compared to normal healthy individuals. Methods: We performed single cell RNA sequencing (scRNA-seq) from pancreata or tumor specimens obtained from 3 healthy human subjects, 3 patients with CP, and 2 individuals with dCCA. After ascribing cell-type identities and delineation of ductal cell clusters, we performed inference of copy number variations as well as functional perturbations at the gene and pathway level in ductal cell from the three patient cohorts - normal, CP and dCCA. Results: scRNA-seq revealed 35 different cell clusters across ~120,000 cells from the three patient cohorts. Based on semi-supervised learning, we identified 13 cell types in our data; additional analysis revealed that the Ductal cell cluster could be further sub-classified into two cell populations with disparate genomic signature. We further identified amplification/duplication of chromosomes 1, 7, 11, 12 and 18 in the Ductal A cluster from the dCCA cohort through two orthogonal approaches. Pseudobulking analysis suggested an upregulation of laminins in Ductal A subcluster, and Ligand-receptor analysis further revealed LAMC2 as a key target gene in the Ductal cell cluster, with putative fibroinflammation mediated by TGFB1 and FGF2 receptors. While laminin upregulation was unique to dCCA and not observed in CP, TGFB1 and FGF2 receptor-driven signaling was a shared feature in ductal cells across both CP and dCCA. Conclusions: We discovered a novel ductal cell population in dCCA that exhibits upregulation of laminins compared to normal pancreas and CP. Further still, the expression of ligand, receptor, and target genes in the dCCA extracellular matrix highlights how the TGFB1-FGF2-LAMC2 axis might be contributing to the desmoplastic process observed in dCCA tumors.
利益披露 Disclosure
M. Chen, None.. J. M. Harrison, None. D. R. Ruddy, Novartis Employment. M. Piquette, Novartis Employment. J. Chang, Novartis Employment. V. Cremasco, Novartis Employment. A. L. Warshaw, None.. C. Fernandez-Del Castillo, None. A. S. Liss, Flare Therapeutics Other, Spouse is employed at Flare and has stock options.. D. Agarwal, None.

← 返回 AACR 2026 检索